OIE Reference Laboratory Reports ActivitiesActivities in 2021

This report has been submitted: 2022-01-14 15:08:30

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Equine viral arteritis
Address of laboratory:	New Haw, Addlestone Surrey KT15 3NB Weybridge UNITED KINGDOM
Tel.:	+44-208069621
Fax:	+44-1932 35 72 39
E-mail address:	falko.steinbach@apha.gov.uk
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Mr Ian Hewett, CEO
Name (including Title and Position) of OIE Reference Expert:	Prof Falko Steinbach, Head of Mammalian Virology
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of te	est performed last year
Indirect diagnostic tests		Nationally	Internationally
SNT	yes	5468	38
Direct diagnostic tests		Nationally	Internationally
Virus isolation	yes	12	0
PCR	yes	34	0

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.

To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
SOUTH AFRICA	May 2021	1	1

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
CHINA (PEOPLE'S REP. OF)	standardising diagnostic testing	e-mail consultation
SAUDI ARABIA	standardising diagnostic testing	e-mail consultation

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

No

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:

We collect data on EVA testing at APHA in the UK

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

We provide the above data for the reports collated by BEVA

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 4

The data collated above are then reported in the Veterinary Record as

Equine disease surveillance: quarterly updates

b) International conferences: 1

Data relating to the 2019 outbreak in the UK were presented at Int Equine Infectious Diseases Conference 2021 (online)

- c) National conferences: 0
- d) Other:

(Provide website address or link to appropriate information) 4

In line with providing our data as mentioned above they are then collated into reports at https://equinesurveillance.org/ under surveillance reports

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

4

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO 9001	ISO9001 certificate 2020-2023.pdf
ISO 17025 lab	ISO17025 Certificate.pdf
ISO 17025 test	1769Testing-Multiple-1.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Virus isolation	UKAS
PCR	UKAS
SNT	UKAS

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
CAREC/OIE Training on Laboratory Techniques for Equine Diseases	11/2021	online/Kazakhstan	speaker	Overview and Technical Aspects of the Equine Diseases Control

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory	exchange information	with other	OIE Reference	Laboratories	designated for	or the same
pathogen or disease?						

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
Determining laboratories capability to conduct serology (organising)	27	⊠Africa ⊠Americas ⊠Asia and Pacific ⊠Europe ⊠Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the

No

25. Additional comments regarding your report:

Our activities were still affected by the SARS-CoV-2 pandemic; not least our expertise in the area of Nidoviruses remained in regular demand.